ABT|Analyst Targets
ABT|Company Info
ABT|Insider Trading
ABT|Fundamentals
ABT|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.41 | - | - |
| Q2'26 | $1.42 | $1.31 | -7.9% |
| Q1'26 | $1.15 | $1.15 | +0.3% |
| Q4'25 | $1.51 | $1.50 | -0.8% |
| Q3'25 | $1.30 | $1.30 | +0.0% |
| Q2'25 | $1.26 | $1.26 | +0.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $13.1B | - | - |
| Q2'26 | $12.6B | $12.6B | -0.2% |
| Q1'26 | $11.0B | $11.2B | +1.5% |
| Q4'25 | $11.9B | $11.5B | -3.9% |
| Q3'25 | - | $11.4B | - |
| Q2'25 | - | $11.1B | - |
ABT|Monthly Returns
Market Data
ABT Stock Snapshot
- Market cap
- 177.12B
- P/E ratio
- 32.6
- Day range
- $101.69 – $104.16
- News sentiment
- 63/100 · Bullish
- Analyst target
- $120.72 (+17.2%)
- Consensus
- Buy · 35 analysts
The chart on ABT has not stabilised: price is in the lower half of its 52-week range and the trend is still down. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.
Reverse DCF
What growth is priced into ABT?
At today's price, Abbott Laboratories needs to grow free cash flow about 5.3% a year for the next 10 years to justify its valuation at a 7.14% cost of capital. Over its actual history it has compounded free cash flow at 1.8% a year, so the market is asking for 3.5 percentage points above its own delivered rate. On that basis ABT looks priced above what its own growth record supports.
- Implied FCF growth
- 5.3%
- Historical FCF CAGR
- 1.8%
- Growth gap
- +3.5 pts
- Verdict
- RICH
- Discount rate (WACC)
- 7.14%
- Beta
- 0.44
Behaviour On Record
What ABT's own history says about today's numbers
- Realized volatility (21d)
- 21.5% 60th pct
- Below its peak
- -27.3%
- vs 200-day average
- -0.1%
- Up days (1y)
- 47%
Abbott Laboratories is currently running 21.5% annualised volatility over the last 21 sessions. Measured against ABT's own 13 years of daily returns rather than a market-wide average, that is the 60th percentile — a little above its own norm, against a typical reading of 19.7%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
ABT is trading -27.3% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -17.2%, and the deepest was -31.9% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits -0.1% from its 200-day moving average. Against every other day in its history, that gap ranks at the 32nd percentile — close to the gap it normally carries. Over the past year ABT closed higher on 47% of sessions, and it is currently 6 sessions into a rising streak.
On October specifically: over 14 years of records, ABT finished the month higher 8 of 14 times, with a median return of +1.8% and an average of +1.5%. Its strongest month historically has been July at +4.4% on average, its weakest September at -1.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: ABT has opened more than 2% away from the prior close in 42 of 3,267 sessions (1.3% of the time), with the largest gaps running +11.5% and -5.2%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, ABT moved an average of 1.9% in the session after earnings, closing higher 2 of those 3 times, with a median move of +1.6% and a largest of -2.0%.
All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against ABT's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of ABT's sector?
Abbott Laboratories sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Medical Devices industry group, ABT ranks 2nd of 15 tracked industries, leading.
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 82
- Industry rank
- #2 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on ABT?
Barclays most recently initiated coverage on Abbott Laboratories to Overweight on Oct 7, 2026 with a price target of $120. Over the last 90 days, coverage has run 2 upgrades against 0 downgrades, a net bullish lean.
- Latest action
- Barclays — Overweight
- 90-day upgrades
- 2
- 90-day downgrades
- 0
- Net rating momentum
- +2
Earnings Release, Scored
What did Abbott Laboratories's latest earnings release say?
Most important lines
- 1
– Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58
Guidance raisedNew this quarter - 2
Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58.
Guidance raisedNew this quarter - 3
Nutrition sales increased $127 million on a sequential basis compared to the first quarter of 2026.
New this quarter
Peers & ETF holders
ABT peers & ETF holders
Medical DevicesMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▲ Buy | 175,556,716 | 10.18% | $22.00B | 2026-01-29 |
| BlackRock, Inc. | ▲ Buy | 152,563,476 | 8.85% | $13.84B | 2026-08-07 |
| Geode Capital Management, LLC | ▲ Buy | 39,219,337 | 2.27% | $3.54B | 2026-08-12 |
| Capital Research Global Investors | ▼ Sell | 36,908,990 | 2.14% | $3.35B | 2026-08-12 |
| Morgan Stanley | ▼ Sell | 26,611,315 | 1.54% | $2.41B | 2026-08-13 |
| Norges Bank | ▼ Sell | 23,354,911 | 1.35% | $2.12B | 2026-08-12 |
| Northern Trust Corp | ▼ Sell | 18,273,301 | 1.06% | $1.66B | 2026-08-13 |
| Bank of America Corp | ▼ Sell | 17,672,543 | 1.02% | $1.60B | 2026-08-14 |
| Goldman Sachs Group Inc | ▲ Buy | 16,760,070 | 0.97% | $1.52B | 2026-08-14 |
| JPMorgan Chase & Co | ▼ Sell | 15,095,898 | 0.88% | $1.40B | 2026-08-12 |
| Wells Fargo & Company | ▼ Sell | 15,177,317 | 0.88% | $1.38B | 2026-08-14 |
| FMR LLC (Fidelity) | ▲ Buy | 13,423,080 | 0.78% | $1.22B | 2026-08-13 |
| Janus Henderson Group plc | ▲ Buy | 8,092,917 | 0.47% | $830.86M | 2026-05-18 |
| Invesco Ltd. | ▼ Sell | 8,817,240 | 0.51% | $800.08M | 2026-08-14 |
| Citadel Advisors LLC | ▲ Buy | 8,597,227 | 0.50% | $780.11M | 2026-09-02 |
| Wellington Management Group LLP | ▼ Sell | 8,304,709 | 0.48% | $753.57M | 2026-08-14 |
| Two Sigma Investments, LP | ▲ Buy | 8,126,315 | 0.47% | $737.38M | 2026-08-14 |
| Marshall Wace, LLP | ▲ Buy | 5,542,438 | 0.32% | $502.92M | 2026-08-13 |
| AQR Capital Management LLC | ▲ Buy | 4,193,058 | 0.24% | $380.48M | 2026-08-14 |
| Millennium Management LLC | ▲ Buy | 3,599,994 | 0.21% | $326.66M | 2026-08-14 |
| AllianceBernstein L.P. | ▼ Sell | 2,999,050 | 0.17% | $307.91M | 2026-08-14 |
| Citigroup Inc | ▲ Buy | 2,621,398 | 0.15% | $237.87M | 2026-08-03 |
| Neuberger Berman Group LLC | ▼ Sell | 2,558,111 | 0.15% | $232.26M | 2026-08-13 |
| Adage Capital Partners GP, L.L.C. | ▲ Buy | 2,332,115 | 0.14% | $211.62M | 2026-08-14 |
| Point72 Asset Management, L.P. | ▲ New | 1,551,929 | 0.09% | $140.82M | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2026-09-18 | 2026-10-12 |
| Richard Dean Dr McCormick | House | GA06 | ▼ Sell | $1K - $15K | 2026-07-30 | 2026-08-14 |
| Mike Kelly | House | PA16 | ▼ Sell | $1K - $15K | 2026-07-17 | 2026-08-12 |
| Richard W. Allen | House | GA12 | ▼ Sell | $15K - $50K | 2026-07-14 | 2026-08-18 |
| Rick Larsen | House | WA02 | ▼ Sell | $1K - $15K | 2026-07-08 | 2026-07-12 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2026-06-16 | 2026-07-02 |
| Richard Dean Dr McCormick | House | GA06 | ▲ Buy | $1K - $15K | 2026-06-12 | 2026-07-09 |
| Josh Gottheimer | House | NJ05 | ▼ Sell | $1K - $15K | 2026-05-27 | 2026-06-03 |
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2026-05-15 | 2026-06-08 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2026-05-12 | 2026-06-12 |
| Richard W. Allen | House | GA12 | ▼ Sell | $15K - $50K | 2026-04-16 | 2026-06-05 |
| Alan Armstrong | Senate | OK | ▼ Sell | $15K - $50K | 2026-03-27 | 2026-07-21 |
| Laura Friedman | House | CA30 | ↔ Exchange | $1K - $15K | 2026-03-24 | 2026-04-17 |
| Richard Dean Dr McCormick | House | GA06 | ▲ Buy | $1K - $15K | 2026-03-19 | 2026-04-07 |
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2026-02-10 | 2026-03-09 |
| Thomas H. Kean | House | NJ07 | ▲ Buy | $1K - $15K | 2026-01-29 | 2026-02-19 |
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2025-12-19 | 2026-01-12 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-12-18 | 2026-01-15 |
| Julia Letlow | House | LA05 | ▼ Sell | $1K - $15K | 2025-12-08 | 2026-01-13 |
| Byron Donalds | House | FL19 | ▼ Sell | $1K - $15K | 2025-12-04 | 2026-01-07 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2025-11-18 | 2025-12-15 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-11-13 | 2025-12-11 |
| Richard Dean Dr McCormick | House | GA06 | ▲ Buy | $1K - $15K | 2025-11-05 | 2025-12-09 |
| Rick Larsen | House | WA02 | ▲ Buy | $1K - $15K | 2025-10-06 | 2025-10-16 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-08-14 | 2025-09-11 |